1) INTRODUCTION
As previously mentioned in part 1 of this review 1 , accelerated atherosclerosis and premature ageing are closely associated with chronic kidney disease (CKD) and particularly with end-stage renal disease (ESRD) [2] [3] [4] [5] . The term chronic kidney diseasemineral and bone disorder (CKD-MBD) was introduced eleven years ago to define a triad of laboratory and bone abnormalities and tissue (mainly vascular) calcifications, all of which are linked to poor hard-outcomes 6, 7 . Currently, bone is considered a new endocrine organ at the heart of CKD-MBD, while there is ongoing controversy as to whether CKD-MBD should be regarded as a real syndrome or not 8, 9 .
The increasing availability of new phosphate (P)-binders (reviewed in reference 1), vitamin D (VD) receptor activators (VDRA) and the innovative development of modulators of the calcium (Ca)-sensing receptor (CaSR) -calcimimetics-have significantly increased our therapeutic armamentarium 10, 11 . Furthermore, the appearance of sevelamer and recognition of the fibroblast growth factor-23 (FGF23)/klotho axis have helped to review paradigms in the pathophysiology of secondary hyperparathyroidism (SHPT) 12, 13 , and to increase awareness of the presence of cardiovascular calcification (CVC) and the need to quantify it 14, 15 . These developments have given rise to the concept that CKD-MBD-related drugs such as non-Ca-based Pbinders may attenuate the accelerated progression of CVC in CKD patients and potentially improve survival [15] [16] [17] [18] . Consequently, other agents such as anti-parathyroid drugs have also been analyzed in this regard.
In order to control the increasing parathyroid hormone (PTH) levels, new VDRA and calcimimetics were introduced that allowed not only medical treatment of previously calcitriol-resistant patients with severe forms of SHPT 19 but also earlier and more effective control of CKD-MBD-related laboratory parameters. Experimental and clinical studies have also shown that some anti-parathyroid agents may attenuate the progression of CVC 20, 21 , potentially leading to improved survival [22] [23] [24] . The number of parathyroidectomies (PTX) has also markedly dropped 25, 26 , and it should not be forgotten that PTX (and PTX-related percutaneous injections of ethanol or VD in parathyroid glands) are not exempt from important risks, especially in the perioperative period and during the year after the procedure 27 , including permanent hypoparathyroidism.
Against this background, the purpose of this article is to provide an update on the contemporary pharmacological control of PTH in the context of CKD-MBD. The first part focused on agents that aim to control P imbalance and this second part covers anti-parathyroid drugs such as VD derivatives and calcimimetics emphasizing their differential effects not only on biochemical parameters but also on tolerance, CVC, and/or hard-outcomes. Related issues such as the very frequent adynamic bone disease (ABD), usually neglected in drug -reviews, and the rare calciphylaxis will also be briefly discussed.
2) VITAMIN D
SHPT is a common consequence of CKD, which not only leads to bone disease but also plays a role in reducing quality of life and increasing mortality of CKD patients [28] [29] [30] [31] . Calcitriol (1,25-(OH)2-VD), as an anti-parathyroid agent, decreases the synthesis of PTH independently of its known hypercalcemic action by acting through its specific receptor (the VD receptor) 32 . The desirable serum PTH target levels and the variability of PTH assays are matters of intense current debate 7, [33] [34] [35] [36] [37] [38] . For instance, Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggest that in CKD stage 5 and 5D, serum PTH levels should be maintained at between 2 and 9 times (2X-9X) the upper normal limits for the used assay 7 , based on the poor quality as a biomarker of PTH in relation to underlying renal bone disease 7, 36 . Other national guidelines continue to support the 2003 National Kidney Foundation (NKF)/Kidney Dialysis Outcomes Quality
Initiative (KDOQI™) recommendation of 150-300 pg/ml (2X-5X) 39, 40, 35 , mainly based on some epidemiological studies describing the lowest mortality rates in this PTH interval 30, 31 . Agreement exists regarding the need for treatment when laboratory values show an increasing trend over time, even within the aforementioned ranges, and the fact that values exceeding 9 times the upper normal limit must be avoided because they represent extremes of risk 7, 34, 39 . As a matter of fact, questions remain about the wide PTH range suggested in the KDIGO guidelines 26, 36 , and there is concern that the acceptance of "very high" values may negatively impact bone quality, result in the progression of parathyroid glands to uncontrollable monoclonal-growth tumor-like nodular hyperplasia and decrease the efficacy of treatment strategies 36 . In this respect, it is well known that higher than normal serum PTH levels are required to maintain bone remodelling in CKD due to the presence of resistance to the action of PTH 41 , while PTH levels above the 150-300 pg/ml range are associated with increases in hospitalizations 26 participants from the DOPPS phases 1-4 (1996-2011) were included, and it was found that median PTH increased from phase 1 to phase 4 in all regions except Japan, where it remained stable. Importantly, compared with the 150-300 pg/ml range, in adjusted models all-cause mortality risk was higher for PTH=301-450 pg/ml (hazard ratio, 1.09; 95% CI, 1.01-1.18) and >600 pg/ml (hazard ratio, 1.23; 95% CI, 1.12-1.34). PTH >600 pg/ml was also associated with a higher risk of cardiovascular mortality and all-cause and cardiovascular hospitalizations. Prescriptions of intravenous VDRA (and cinacalcet) increased and PTX rates decreased in all regions over time. In a subgroup analysis of 5,387 patients not receiving anti-parathyroid agents and without prior PTX, very low serum PTH levels (<50 pg/ml) were associated with increased mortality risk (hazard ratio, 1.25; 95% confidence interval, 1.04-1.51).
On the other hand, there are also serious concerns about normalizing serum PTH levels in CKD stages 3-5 since moderate elevations of PTH may serve as a beneficial adaptive response (with improvements in phosphaturia or bone turnover) 36 . All these results underline the urgent need for additional research into PTH targets, both in dialysis and non-dialysis patients, as well as the concomitant use of other risk factors and biomarkers in order to better define appropriately individualized clinical practice. Thus, it seems clear that old protocols using just serum PTH levels for correlation with bone turnover and/or survival are inadequate in terms of sensitivity and specificity. Other factors such as Ca, P, CVC should also be taken into account; nevertheless, in patients with CKD and elevated or rising PTH, it is still suggested that VD derivatives, calcimimetics or a combination thereof may be used to lower PTH (evidence 2B) 7 .
Monitoring of alkaline phosphatase activity (especially bone-specific) in combination with PTH may also be helpful to increase specificity 44,45 .
2.1) NATIVE VITAMIN D
It is well known that VD deficiency is common both in the general population inhibitor (increasing the half-life of active VD by decreasing its clearance) 76 .
Lunacalcipol differs from CTA091 in that it also has the ability to activate VDRmediated transcription and suppresses PTH synthesis at doses which do not affect experimental Ca and P levels 76 . However, changes in US market dynamics relating to dialysis treatment seem to delay its clinical development.
3) CALCIMIMETICS.
3.1) CINACALCET
As mentioned before, most traditional therapies for SHPT have entailed correction of reduced Ca intake and absorption in CKD patients, correction of hypocalcemia and excessive production of PTH by administration of Ca salts, supraphysiological Ca levels in the dialysate, use of VDRA, and prevention of hyperphosphatemia by means of Ca-based P-binders 1, 80 . However, these therapies have been limited by the occurrence of hyperphosphatemia (VDRA) and hypercalcemia, a lack of specificity, restricted long-term efficacy, and potential vascular toxicity 11, 24, 81 .
On the other hand, surgical PTX is not exempt from risks 27 . The identification and cloning of CaSR in the 1990's prompted the development of calcimimetics and calcilytic agents 82 . Cinacalcet, the first clinically available activator of the CaSR (calcimimetic), represents a completely new mechanism of action and extends the armamentarium against SHPT in dialysis patients and primary hyperparathyroidism 24, 83 ( Table 1) .
It has been shown that cinacalcet, when tolerated, is very effective in reducing abnormal circulating levels of PTH, Ca, P, CaxP product and, importantly, Although significant changes in the volume of coronary artery calcifications were described, results with respect to the predefined primary end-point of the study (surface)
did not strictly reach statistical significance (p=0.07). Two recent post-hoc analyses suggested that cardiac valve calcification was a predictor of coronary artery calcification progression and, potentially, of greater cardiovascular vulnerability 85 and demonstrated that treatment with cinacalcet had statistically significant beneficial effects among participants who adhered to the prespecified protocol 86 . Second, the EVOLVE RCT did not reach its primary composite end-point (all-cause mortality and cardiovascular events) after an unadjusted intention to-treat (ITT)-based analysis 22 .
These results were supported by a recent meta-analysis, mainly driven by this negative EVOLVE primary result, which included other heterogeneous studies with different designs 87 . However, we do believe that it is important to emphasize that prespecified secondary ITT adjusted analysis revealed a nominally significant improvement in survival in the cinacalcet group 24, 22 . Thus, the effect of cinacalcet was significantly more pronounced among patients aged ≥65 years in secondary and post-hoc however, it unquestionably improves the achievement of target levels for all metabolic abnormalities associated with CKD-MBD and mortality 91, 92 . A summary of negative and positive aspects of the EVOLVE study is presented in Table 2 .
It has been recently reviewed the practical use of calcimimetics in dialysis patients assessing and advising how to circumvent the most frequent adverse events such as nausea and vomiting (Table 3) , hypocalcemia, PTH oversuppression and QTprolongation, among others, with the goal of potentially improving clinical practice and patient adherence 24 . Beyond the influence of cost in prescription rates 93 , persistence of treatment among patients remains low despite all the beneficial effects associated with cinacalcet 93,92,94 .
3.2) ETELCALCETIDE (AMG416)
Etelcalcetide ( observed that a substantial proportion of subjects treated with etelcalcetide achieved PTH ≤300 pg/mL and a ≥30% reduction in PTH from baseline, supporting the continued development of etelcalcetide. The observed decreases in serum-corrected Ca were well tolerated and serum P levels also tended to decrease. Etelcalcetide pharmacokinetics have also been recently published 98 .
The results of a second placebo-controlled Phase III study in dialysis patients evaluating the effect of etelcalcetide on the treatment of SHPT were recently announced 99, 100 . The study's primary endpoint was the proportion of patients with a > 30% reduction from baseline in PTH levels during an efficacy assessment phase defined as weeks 20-27 of the study. In the etelcalcetide group, 74% of patients achieved the primary endpoint, compared with 8.3% of patients in the placebo group. Secondary endpoints included the percentage change in serum P (-7.7% and -1.3% in the etelcalcetide and placebo arms, respectively) and corrected Ca concentrations (-7.3% and 1.2%, respectively). Both of these secondary endpoint results were statistically significant. Treatment-emergent adverse events were reported in 92% of patients who received etelcalcetide and 79% of patients receiving placebo. The most frequently reported adverse event was asymptomatic reduction in Ca; symptomatic hypocalcemia was reported in 7.2% of patients who received etelcalcetide compared with 0.4% in the placebo group 100 . The proportions of patients reporting muscle spasms, diarrhea, nausea, and vomiting were higher in the etelcalcetide group than in the placebo group 99, 100 .
Another Phase III, head-to-head, double-dummy, placebo-controlled study of etelcalcetide and cinacalcet has also been conducted to compare their efficacy and tolerability. It has been announced that treatment with i.v. etelcalcetide achieved >50%
and >30% reductions in PTH in more patients compared with cinacalcet, while, somewhat surprisingly, nausea and vomiting did not seem to differ 101 . Thus, it is currently unclear whether etelcalcetide will have fewer adverse GI effects compared with oral cinacalcet. The i.v. route may also offer a potential reduction in the risk of drug-drug interactions 96 . A numerical imbalance in cardiac failure was observed in this study, for which a causal relationship to etelcacetide could not be established 101 .
Hypocalcemia was seen more frequently with etelcalcetide and the safety profiles appeared to be comparable although more prolonged clinical experience is definitely required 101 .
3.3) NEW CALCIMIMETICS
Two other oral CaSR modulators are in Phase II development (KHK-7580 and ASP7991) 10 . ASP7991 has been shown to significantly decrease PTH levels in a rat model of SHPT and may have less potential for CYP-enzyme-mediated drug-drug interactions than cinacalcet 10 . Another calcimimetic compound, LEO 27847, has been evaluated in a Phase I study for the treatment of SHPT, but no additional information regarding its development is available 10 .
4) ADYNAMIC BONE DISEASE
Adynamic bone disease (ABD) is a well-recognized clinical entity in the CKD-MBD complex 102, 103 . Although the gold-standard diagnostic method is bone biopsy, the presence of low circulating PTH and low bone-specific alkaline phosphatase levels may be suggestive of ABD 44 . In the most recent bone histomorphormetry study before and after long-term treatment with an antiparathyroid agent (cinacalcet), no ABD was observed among patients with PTH ≥ 300 pg/ml, Ca ≥ 8.4 mg/dl and bone-specific alkaline phosphatase > 20.9 ng/ml, although 22 out of 146 patients had normal bone histology 45 .
ABD is increasing in prevalence relative to other forms of renal osteodystrophy and is becoming the most frequent type of bone lesion in some series 7, 102 It is potentially linked to fracture risk and progression of CVC. Among many other factors (recently reviewed in reference 103), drug-induced oversuppression of PTH may contribute to this low-turnover bone state 45 . Thus, prevention of sustained PTH levels <2 times the upper limit of normality, especially in the steadily growing proportions of diabetic, white, and elderly patients, is of the outmost importance (Table 4 ). In the recent COSMOS study, in patients with baseline PTH levels below 168 pg/ml (mean 89 pg/ml), increases in PTH were associated with a lower risk of mortality 34 . Recombinant PTH has been used in casereports 104 . The potential use of Natpara®, released to control hypocalcemia in patients with hypoparathyroidism, or antisclerostin monoclonal antibodies remains to be tested 103 .
5) CALCIPHYLAXIS
Calciphylaxis, or calcific uremic arteriolopathy, is a rare condition and continues to represent a clinical challenge 105, 106 . In addition to existing pharmacological treatments, and that cinacalcet appears to reduce the incidence of calciphylaxis in hemodialysis patients 107 , sodium thiosulfate has recently been introduced in the armamentarium against calciphylaxis. It may also attenuate the rate of progression of CVC but at the expense of reduced bone mineral density at the hip 108 . We have already mentioned that avoidance of an excessive P load is currently considered one of the key issues in the management of CKD-MBD 1 . We also previously reported that best treatment remains to be defined, especially considering the low efficiency, poor patient adherence, potential toxicity and cost of P-binders 1 . Retail prices are currently decreasing due to the advent of generic drugs after expiry of patent protection, and this may change some subjective perceptions.
In this second part of the article we have reviewed specific anti-parathyroid treatment, including several VDRA (some of which are described as selective VDRA), calcimimetics, and combinations thereof. Guidelines suggest that VDRA treatment may be used in patients with stage 3-5 CKD who are not on dialysis and in whom PTH is progressively rising and remains persistently above the upper limit of normal for the assay despite correction of modifiable factors. On the other hand, VDRA and/or calcimimetics are suggested in patients with CKD stage 5D and elevated or rising PTH, bearing in mind that it is reasonable for the initial drug selection to be based on Ca and P levels as well as on other aspects of CKD-MBD such as cardiovascular calcification.
Determination of CVC fits into the paradigm of personalized medicine 112 , and we believe that an assessment for CVC is therefore warranted at least in some patients, including any in whom the carying physician decides that knowledge of the presence of CVC may impact therapeutic decisions (i.e., Ca-vs non-Ca based P-binders; calcitriol or alfacalcidol vs paricalcitol or maxacalcitol; VDRA vs calcimimetics) 1, 112, 113 .
Actually, in the recent commentary from a KDIGO controversies conference 36 , it was stated that "the group was unanimous in their assessment of the clinical significance of cardiovascular calcification and the conclusion that cardiovascular calcification should be considered for guidance of CKD-MBD management".
Although the link between intervention and outcomes when progression of CVC is attenuated has not been conclusively demonstrated, cheap and readily accessible plain X-rays and/or echocardiography may help to define the initial best and safest treatments, at least until we are able to use other therapeutic means at earlier stages of the accelerated atheromatosis process 112,114 .
7) EXPERT OPINION
PTH is a poor biomarker in relation to underlying bone disease, at least partially due to the presence of multifactorial resistance to the renal and skeletal actions of PTH in uremia and the variability of PTH assays. For the moment and until deciphering the way to circumvent these problems, it is clear that serum PTH levels should be maintained higher than normal in dialysis patients. Thus, KDIGO guidelines suggest that "serum PTH levels should be maintained at between 2X-9X the upper normal limits for the used assay" in patients with CKD stage 5D; nevertheless, we follow the Spanish adaptation of the KDIGO guidelines which initially aim at 2-5 times the upper limit of normality to free up space and safely avoid KDIGO extremes of risk (<2 or >9 times the upper normal limit) 35 phosphatemic profile, may yield specific differential beneficial effects at the tissue and molecular levels (e.g. slower CVC progression), but this has only been shown under experimental conditions, and no RCT has ever been performed. We believe that although it has not been proven that VDRA improve hard-outcomes, it would be insensitive to completely dismiss the accumulated robust data. In this regard, paricalcitol shares, and sometimes has been shown to selectively improves, pleiotropic VD-related systemic effects 68, 75 . Questions about costs in relation to benefits may be raised, but it is to be borne in mind that expiry of patent protection will decrease retail prices.
Practical issues regarding the use of VDRA have recently been reported 115, 116 .
Briefly, we use paricalcitol as the first-line VDRA due to its wider therapeutic window as compared with calcitriol, especially in patients with CVC, diabetics, and patients treated with coumadin derivatives. In adults, in order to avoid unacceptably and unnecessarily rapid PTH suppression, we calculate the initial dose based on baseline serum intact PTH (iPTH) levels (µg of paricalcitol iv /dialysis session = baseline iPTH in pg/mL / 100-120) instead of the common iPTH/80 reported in the summary of product characteristics. Conversion of intravenous paricalcitol from calcitriol is smoother using a 1:3 calcitriol to paricalcitol conversion ratio 117 
Article highlights
• CKD is linked to an extremely important and independent increase in mortality, and mineral and bone disorders (MBD) explain at least part of this disproportionate risk
• Treatment of CKD-MBD requires an integral approach, addressing all 3 components of the CKD-MBD triad (including the presence of CVC)
• CKD-MBD and secondary hyperparahtyroidism are common and costly manifestations of CKD
• Vitamin D deficiency is common both in the general population and in patients with CKD, and it is associated with poor outcomes • The ADVANCE and EVOLVE RCTs provide important clues towards improvement of hard outcomes in dialysis patients
• Etelcalcetide represents a novel iv agonist of the calcium-sensing receptor
• Combination of anti-parathyroid agents is a feasible clinical option
• Low PTH levels (< 2 times the upper limit of normality for the assay) should be avoided since adynamic bone disease is associated to poor outcomes
• Increasing trends in PTH levels should be treated and PTH levels > 9 times the upper limit of normality should be definitely avoided Nominally significant decreases in heart failure, parathyroidectomy, clinically reported bone fractures, and calciphylaxis (secondary endpoints)
Known and expected secondary effects Table 3 . Strategies to control gastrointestinal symptoms related to cinacalcet
• Inform patients about the importance of controlling CKD-MBD and its impact on cardiovascular outcomes
• Inform patients that although cinacalcet may cause GI effects, it is not an ulcerinducing drug
• Give cinacalcet after the main meal or in the evening Phosphate (and/or FGF23) control: (P-binders) (see Part I) 1 • Achieve P levels as close to normality as possible with reasonable measures, including optimization of dialysis*
• Avoid additives by all possible means, prioritize a balanced vegetarian vs animal dietary protein source and limit ↑ P/protein index foods
• Prioritize P-binder prescription over unsupervised non-specific protein diet restriction
• If very high serum PTH and P levels are present, consider the possibility that P may NOT be of intestinal origin.
• Personalize choice of P-binder prescription depending on patient preferences, CKD stage (dialysis vs non-dialysis), presence/absence/degree of VC, concomitant therapies (i.e., VDRA, calcimimetics) and side effect profile (i.e., palatability, constipation, diarrhea)
• Avoid Ca-based P-binders in patients with hypercalcemia, low PTH levels, and/or ABD. Avoid or limit Ca-based P-binders in diabetics, patients with VC, and patients treated with coumadin.
• Combination of P-binders is possible and inhibition of intestinal transporters may soon become an alternative or add-on therapy to improve clinical effectiveness.
PTH control (specific anti-parathyroid treatment)
• Aim for iPTH levels between 2 and 5 times the upper limit of normality and avoid extremes of risk (<2X or >9X).
• Treat tendencies and do not respond to minor variations in PTH.
• Initial drug selection may be based on CKD stage, Ca and P levels as well as on other aspects of CKD-MBD (e.g., CVC).
• Cinacalcet is not approved for the treatment of secondary hyperparathyroidism in CKD stages 3-5
• In CKD stage 5D, use vitamin D and calcimimetics in combination to improve efficacy with fewer secondary effects, eventually always considering the Ca and P levels
• Selective VDRA (paricalcitol) may provide a wider therapeutic window, especially in those with a trend toward hypercalcemia or hyperphosphatemia, diabetic patients, and those prone to VC (experimental).
• Cinacalcet is considered first-line treatment in hypercalcemic (and perhaps significantly hyperphosphatemic) dialysis patients.
• I.V. etelcalcetide may improve compliance CKD-MBD: chronic kidney disease-mineral and bone disorder; P: phosphate; Ca:
calcium; CVC: vascular calcification; ABD: adynamic bone disease; VDRA: vitamin D receptor activators; iPTH: intact parathyroid hormone; i.v.: intravenous; <2X->9X: less than 2 times or more than 9 times the upper limit of normality for the assay.
*Curiously, just in the summary of product characteristics of non-Ca based P binders it is stated that they are indicated for the control of hyperphosphatemia in adult patients with CKD not on dialysis only with serum P > 1.78 mmol/l (5.5 mg/dl).
